Latest Glucagon-like peptide-1 Stories
NORWALK, Conn., Feb.
JERUSALEM, January 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
The Lack of Reimbursement for DPP-IV Inhibitors and GLP-1 Analogues Hinders Their Uptake Among Chinese Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., Dec.
LONDON and BOSTON, November 20, 2014 /PRNewswire/ -- Project to develop first-in-class selective and orally available GLP-1 receptor antagonist for treating severe
- Intarcia grants Servier exclusive rights to ITCA 650 in ex-U.S./Japan territories; Intarcia retains full control of ITCA 650 in the United States and plans another partner in Japan.
SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders -
New research published in Diabetologia suggests that consuming whey protein before a regular breakfast reduces the blood sugar spikes seen after meals and also improves the body's insulin response.
Agents That Can Elicit Greater Weight Loss Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass., July 7, 2014 /PRNewswire/
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.